Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 known ✓ | Q13464 | 2/20 | 0.92 |
| ▸ | PDGFRB known ✓ | P09619 | 1/20 | 0.45 |
| ▸ | KIT known ✓ | P10721 | 1/20 | 0.45 |
| ▸ | MAP3K5 | Q99683 | 15/20 | 0.92 |
| ▸ | RET | P07949 | 2/20 | 0.92 |
| ▸ | CDK2 | P24941 | 2/20 | 0.92 |
| ▸ | GSK3B | P49841 | 2/20 | 0.92 |
| ▸ | ITK | Q08881 | 2/20 | 0.92 |
| ▸ | MERTK | Q12866 | 2/20 | 0.92 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.92 |
| ▸ | MAP3K6 | O95382 | 2/20 | 0.91 |
| ▸ | CLK2 | P49760 | 3/20 | 0.46 |
| ▸ | CLK1 | P49759 | 2/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | FLT3 | P36888 | 1/20 | 0.45 |
| ▸ | CLK3 | P49761 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.45 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3486701 | 0.96 | MAP3K5 (1.00) | MAP3K5RETCDK2GSK3BITK | |
| Hydrochloric Acid SCHEMBL3485627 | 0.95 | MAP3K5 (1.00) | MAP3K5RETCDK2GSK3BITK | |
| SCHEMBL3486598 | 0.89 | MAP3K5 (1.00) | MAP3K5RETCDK2GSK3BITK | |
| Hydrochloric Acid SCHEMBL3486523 | 0.88 | MAP3K5 (0.98) | MAP3K5RETCDK2GSK3BITK | |
| SCHEMBL3486207 | 0.88 | MAP3K5 (0.75) | MAP3K5RETCDK2GSK3BITK | |
| SCHEMBL3486268 | 0.88 | MAP3K5 (0.79) | MAP3K5RETCDK2GSK3BITK | |
| SCHEMBL3486643 | 0.88 | MAP3K5 (0.71) | MAP3K5RETCDK2GSK3BITK | |
| SCHEMBL3485441 | 0.87 | MAP3K5 (0.83) | MAP3K5RETCDK2GSK3BITK | |
| SCHEMBL3486464 | 0.86 | MAP3K5 (1.00) | MAP3K5RETCDK2GSK3BITK | |
| SCHEMBL3486875 | 0.86 | MAP3K5 (0.80) | MAP3K5RETCDK2GSK3BITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2010-02-04 | — | — | US | disclosed |
| EP-2058309-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | IRAK1, IL1R1, IRAK2 | ROCK1 9/4885PDGFRB 1828/4885KIT 1273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.